Send us Feedback

Advanced Medical Optics (EYE)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
OPERATING METRICS
REVENUE SOURCES
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

EYE » Topics » Ophthalmic Surgical Sales

This excerpt taken from the EYE 8-K filed Feb 14, 2006.
Ophthalmic Surgical Sales
 

Ophthalmic surgical revenue grew 49.9 percent in 2005 to $619.8 million. There was virtually no impact related to foreign currency for the full year. In the fourth quarter of 2005, sales were $186.5 million, up 38.1 percent, including a 5.1 percent decrease related to foreign currency. The annual and fourth-quarter growth illustrated the impacts of recent acquisitions, increased sales of technologically advanced products and declining sales of non-strategic products being discontinued. Below are highlights of AMO’s ophthalmic surgical product categories. Growth rates reflect comparisons to the same periods in 2004 and include the impacts of foreign currency.

 

Cataract/Implant:

 

•             For the year, total cataract/implant sales rose 23 percent to $496.4 million, reflecting the full year contribution of the 2004 Pfizer acquisition and increased sales of value-added technologically advanced products. In the fourth quarter, sales growth related to these advanced products was partially offset by the accelerated phase-out of older-generation products and a negative currency effect, resulting in a 0.02 percent sales decline to $132.3 million.

 

•             Total IOL sales grew 10 percent to $259.1 million in 2005. Fourth-quarter sales rose 1.5 percent to $69.4 million. This performance was attributed primarily to increased sales of Tecnis® and other premium IOLs, as well as the accelerated phase-out of older-generation silicone and PMMA (polymethyl methacrylate) IOLs. Together, the company’s refractive IOLs – Tecnis® Multifocal, ReZoomTM and VerisyseTM – contributed $22.9 million to total 2005 IOL sales.

 

•             Viscoelastics sales grew 76.6 percent in 2005 to $131.2 million, reflecting primarily the addition of the Healon® line, which the company acquired with the Pfizer transaction.

 

3


 

Fourth-quarter viscoelastics sales declined 9.9 percent to $33.5 million, as Healon® sales performance was masked by declining sales of discontinued viscoelastics, reimbursement pressures in certain international markets and unfavorable foreign currency translations.

 

•             Phacoemulsification sales rose 7.5 percent in 2005 to $80.8 million. Fourth-quarter sales were up 7.9 percent to $22.5 million. Strong sales of AMO’s proprietary Sovereign®  systems with WhiteStar® technology, as well as the surgical packs and accessories that support these systems, led this growth.

 

Laser Vision Correction (LVC):

 

•             LVC sales were $123.4 million in 2005. Fourth-quarter LVC sales were $54.2, up 26 percent versus the combined VISX LVC and AMO microkeratome sales in the year-ago period. The increase reflects growth in the U.S. LVC business, increased sales related to the company’s international expansion and strong microkeratome sales.

 

•             LVC licensing and related sales for 2005 totaled $70.8 million. Fourth-quarter sales of $29.9 million reflected an approximate 10 percent increase over VISX’s reported licensing and related sales in the same period last year. The improvement is attributed to an increase in the mix of CustomVue® LASIK procedures.

 

•             LVC system sales in 2005 were $27.1 million. Fourth-quarter sales of $14.2 million represented an approximate 79 percent increase compared to VISX’s reported system sales in the same period last year. The rise is due primarily to the increase in new unit placements and CustomVue® upgrades in targeted international markets, as well as the continued rollout of Iris Registration in the U.S. LVC service and parts sales in 2005 were $13.2 million, including $5.9 million in the fourth quarter. The fourth-quarter performance reflected an increase of approximately 13 percent compared to VISX’s reported service and parts sales in the same period last year.

 

This excerpt taken from the EYE 8-K filed Nov 2, 2005.

Ophthalmic Surgical Sales

 

Ophthalmic surgical sales grew 50.4 percent in the quarter to $170.6 million, including a 0.3 percent positive impact related to foreign currency. Sales related to the VISX acquisition of $47.7 million accounted for 42.0 percent of the growth. Quarterly ophthalmic surgical sales highlights are provided below. Growth rates reflect comparisons to the same period in 2004.

 

Cataract/Implant:

 

  •   Total cataract/implant sales rose 8.6 percent to $120.3 million, reflecting strong growth in branded viscoelastics and phacoemulsification products and providing the first year-over-year sales comparison for the June 2004 Pfizer transaction.

 

  •   Sales of intraocular lenses (IOLs) grew 6.1 percent to $62.3 million, primarily as a result of focus on the company’s branded IOLs and the continuing phase-out of older-generation products.

 

  •   Sales of viscoelastics rose 2.0 percent to $28.9 million, resulting primarily from an 11.4 percent increase in sales of the company’s Healon® products and declines in older-generation viscoelastics that the company is actively discontinuing.

 

  •   Sales of phacoemulsification products rose 15.1 percent to $19.5 million due to strong sales of the company’s proprietary Sovereign® systems with WhiteStar® technology.

 

Laser Vision Correction:

 

  •   Total laser vision correction (LVC) sales, which included the benefits of the VISX acquisition and AMO microkeratome sales, rose to $50.4 million, compared to AMO microkeratome and other related sales of $2.8 million in the same period last year.

 

  •   LVC licensing and related sales totaled $31.2 million, up approximately 15 percent compared to VISX’s reported licensing and related sales in the same period last year. The improvement reflects higher CustomVue™ procedures, due in part to the fact that AMO has the widest treatment range of wavefront-guided approvals in the U.S.

 

  •   LVC system sales were $11.1 million in the quarter, up approximately 71 percent compared to VISX’s reported system sales in the same period last year. The rise reflects the increase in new unit placements in targeted international markets, as well as the September rollout of Iris Registration in the U.S. LVC service and parts sales were $5.4 million in the quarter, up approximately 7 percent compared to VISX’s reported service and parts sales in the same period last year.

 

EXCERPTS ON THIS PAGE:

8-K
Feb 14, 2006
8-K
Nov 2, 2005

RELATED TOPICS for EYE:

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki